CompletedNot Applicable

Brain Areas of Time-To-Contact Perception: an Awake Surgery Study

France120 participantsStarted 2019-09-16

Plain-language summary

During a brain surgery targeted to remove a brain tumor, the neurosurgeon wakes up the patient to delimit the tumor area exactly, and identify the surrounding areas, to limit the surgery damages. The present project aims at testing the patient in this awake phase to determine the brain areas implied in time to contact (TTC) perception, a function that allows determining the arrival time of moving objects and used in many tasks of our daily life.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For the patients: * Brain tumor that does not affect the dominant hand motricity. The patient that have a tumor in an area targeted for a cortical stimulation will be automatically enrolled within the Pre-End group. * Who will agree with all terms and sign the experimental agreement * Correct or corrected vision, as allowed by the surgery constraints * With no known oculomotor abnormalities (list of exclusion in Annexe) * Affiliated to a social security system For the control group: * Who will agree with all terms and sign the experimental agreement * Correct or corrected vision * With no known oculomotor abnormalities. * Affiliated to a social security system Exclusion Criteria: For the patients: * Brain tumor located in the occipital area * Legally protected patient, or with unknown ability to sign the experimental agreement, as determined by the medical team. * Medical background of neurological diseases of the central nervous system, as Parkinson, Alzheimer, stroke * Pregnancy For the control group: * Legally protected patient, or with unknown ability to sign the experimental agreement, as determined by the medical team. * Medical background of neurological diseases of the central nervous system, as Parkinson, Alzheimer, stroke * Pregnancy

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Cerebral mapping

Timeframe: 61 months

Trial details

NCT IDNCT04128306

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-29

View on ClinicalTrials.gov More Brain Tumors trials